These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38662778)

  • 41. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
    Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
    Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S; Di Giorgio C; Distrutti E
    Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
    Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
    Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.
    Lu D; Liu Y; Luo Y; Zhao J; Feng C; Xue L; Xu J; Wang Q; Yan T; Xiao P; Krausz KW; Gonzalez FJ; Xie C
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Feb; 1867(2):159089. PubMed ID: 34856412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
    Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
    Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
    Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
    Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
    Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
    Shah RA; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice.
    Iracheta-Vellve A; Calenda CD; Petrasek J; Ambade A; Kodys K; Adorini L; Szabo G
    Hepatol Commun; 2018 Nov; 2(11):1379-1391. PubMed ID: 30411084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
    Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
    Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
    Gege C; Hambruch E; Hambruch N; Kinzel O; Kremoser C
    Handb Exp Pharmacol; 2019; 256():167-205. PubMed ID: 31197565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
    Alkhouri N; LaCerte C; Edwards J; Poordad F; Lawitz E; Lee L; Karan S; Sawhney S; Erickson M; MacConell L; Zaru L; Chen J; Campagna J
    Liver Int; 2024 Apr; 44(4):966-978. PubMed ID: 38293761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.